Regeneron Pharmaceuticals' Deferred Taxes fell 1702.36% to $232.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $785.4 million, marking a year-over-year increase of 371.06%. This contributed to the annual value of $785.4 million for FY2025, which is 371.06% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Deferred Taxes stood at $232.5 million, which was down 1702.36% from $278.6 million recorded in Q3 2025.
Regeneron Pharmaceuticals' Deferred Taxes' 5-year high stood at $286.3 million during Q4 2023, with a 5-year trough of -$41.7 million in Q2 2021.
In the last 5 years, Regeneron Pharmaceuticals' Deferred Taxes had a median value of $179.5 million in 2024 and averaged $163.7 million.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Deferred Taxes crashed by 710000.0% in 2021, and later surged by 232772.28% in 2022.
Regeneron Pharmaceuticals' Deferred Taxes (Quarter) stood at $205.9 million in 2021, then soared by 35.84% to $279.7 million in 2022, then rose by 2.36% to $286.3 million in 2023, then fell by 2.13% to $280.2 million in 2024, then decreased by 17.02% to $232.5 million in 2025.
Its last three reported values are $232.5 million in Q4 2025, $278.6 million for Q3 2025, and $135.2 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value